Home » Consumer Goods » Biologics CDMO Secondary Packaging Market

Biologics CDMO Secondary Packaging Market By Secondary Packaging Type (Boxes, Cartons, Labels & Leaflets, Tray Packs / Clamshells, Kitting & Bundling, Serialized Packaging (Track & Trace), Cold Chain Secondary Packaging, Others); By Compatible Primary Package Type (Ampoules, Blister Packs, Cartridges, Vials, Bottles, Prefilled Syringes, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Biologics CDMO Secondary Packaging Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-09-10
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Biologics CDMO Secondary Packaging Market

Summary
Table Of Content
Request Free Sample

Market Overview

Global Biologics CDMO Secondary Packaging Market size was valued at USD 1,382.93 million in 2018 to USD 2,267.62 million in 2024 and is anticipated to reach USD 4,465.69 million by 2032, at a CAGR of 8.23% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Biologics CDMO Secondary Packaging Market Size 2024	USD 2,267.62 million
Biologics CDMO Secondary Packaging Market, CAGR	8.23%
Biologics CDMO Secondary Packaging Market Size 2032	USD 4,465.69 million

The Global Biologics CDMO Secondary Packaging Market is shaped by leading players including WuXi Biologics, FUJIFILM Diosynth, Samsung Biologics, Thermo Fisher Scientific, Catalent, Lonza, PCI Pharma Services, Vetter Pharma, Almac Group, Sharp, and Recipharm. These companies dominate through advanced serialization, cold chain packaging, and patient-centric kitting solutions that align with global compliance standards. Their strategic investments in digital packaging technologies and regional expansions strengthen competitive positioning. North America leads the market with a 37% share in 2024, supported by strong pharmaceutical outsourcing, biologics pipelines, and strict regulatory frameworks, establishing it as the most influential region globally.

Biologics CDMO Secondary Packaging Markett size

Market Insights

The Global Biologics CDMO Secondary Packaging Market was valued at USD 2,267.62 million in 2024 and is projected to reach USD 4,465.69 million by 2032.
Boxes lead with 28% share among secondary packaging types, followed by cartons at 18% and labels and leaflets at 14%, reflecting compliance and safety requirements.
Vials dominate with 32% share in compatible primary packaging, while prefilled syringes (18%) and ampoules (15%) also drive demand through vaccines and self-administration formats.
North America holds 37% share in 2024, supported by strong outsourcing, R&D, vaccine production, and advanced serialization adoption across biologics supply chains.
Key players such as WuXi Biologics, FUJIFILM Diosynth, Samsung Biologics, Thermo Fisher, Catalent, Lonza, PCI Pharma Services, Vetter, and Almac Group strengthen market competitiveness.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segment Insights

By Secondary Packaging Type

Boxes dominate the Global Biologics CDMO Secondary Packaging Market, holding about 28% share. Their strength lies in broad applicability, cost efficiency, and ability to protect bulk biologics during storage and transport. Cartons follow with 18% share, driven by retail-ready formats and anti-counterfeit features, while labels and leaflets account for 14%, supported by regulatory mandates for patient safety and multilingual compliance. Prefilled syringe kits, serialization, and cold chain packaging continue to expand, reflecting the growing need for patient-centric delivery and stringent traceability.

For instance, WuXi Biologics expanded its prefilled syringe assembly and secondary packaging capability at its Germany facility to meet rising demand for patient-ready biologics delivery formats.

By Compatible Primary Package Type

Vials lead this segment with a commanding 32% share, fueled by their extensive use in vaccines and monoclonal antibodies. Prefilled syringes hold about 18% share, benefiting from convenience and rising home-care adoption. Ampoules and blister packs remain important with 15% and 12% shares, respectively, while cartridges secure 10% due to the popularity of auto-injectors and pens. Bottles (8%) and other novel formats (5%) play supportive roles, particularly in advanced therapies and clinical trials requiring customized secondary packaging.

For instance, West Pharmaceutical Services launched NovaPure cartridges specifically designed for auto-injectors and insulin pens, reflecting the increasing demand for cartridge-based delivery in biologics.

Market Overview

Rising Demand for Biologics and Vaccines

The expansion of biologics and vaccine pipelines fuels steady growth in the Global Biologics CDMO Secondary Packaging Market. Increased prevalence of chronic diseases and infectious outbreaks drives large-scale production of injectable therapies. This creates significant demand for reliable packaging solutions such as boxes, vials, and cold chain formats to ensure product integrity. CDMOs play a vital role by offering scalable and compliant secondary packaging tailored for biologics. The segment benefits from heightened pharmaceutical outsourcing trends, ensuring efficient market access.

For instance, Argonaut Manufacturing Services expanded its Carlsbad facility with a new filling line capable of supporting clinical and commercial packaging of vials, syringes, and cartridges to more than quadruple its existing fill-finish operations.

Regulatory Emphasis on Serialization and Traceability

Global regulations mandating serialization, tamper-evidence, and secure labeling drive rapid adoption of advanced packaging technologies. Biologics CDMOs integrate serialization solutions into cartons, labels, and kitting formats to combat counterfeiting and ensure supply chain transparency. Track-and-trace requirements across North America, Europe, and Asia-Pacific create strong opportunities for CDMOs specializing in compliant packaging. This driver significantly boosts investments in digital packaging infrastructure and software-enabled monitoring, positioning secondary packaging as a critical enabler of regulatory adherence and patient safety.

For instance, Optel Group launched an integrated software platform that supports multi-level serialization and aggregation for biologics CDMOs, boosting regulatory compliance and supply chain transparency.

Growth of Cold Chain Logistics for Advanced Therapies

The rise of temperature-sensitive biologics, including cell and gene therapies, is expanding demand for cold chain secondary packaging. Specialized formats such as insulated shippers and phase-change packs are essential for maintaining stability during global distribution. CDMOs invest heavily in cryogenic packaging capabilities to meet the needs of clinical trials and commercial supply. As personalized medicines and specialty biologics expand, cold chain solutions create sustained growth. This driver highlights the market’s alignment with evolving therapeutic portfolios and patient-centric delivery models.

Key Trends & Opportunities

Shift Toward Patient-Centric and Home-Care Packaging

Patient convenience is reshaping biologics packaging, creating opportunities for kitting and prefilled syringe bundles. With more biologics designed for self-administration, CDMOs are focusing on secondary packaging that combines drug, device, and instructions in integrated kits. This trend supports adherence, reduces dosing errors, and meets healthcare system goals of decentralizing care. It also opens opportunities for customized formats tailored to patient populations, boosting demand for flexible and innovative packaging solutions.

For instance, in April 2025, PCI Pharma Services announced the acquisition of Ajinomoto Althea, expanding its flexible biologics manufacturing capabilities to include new facilities for prefilled syringes and cartridges.

Digital Integration and Smart Packaging Solutions

Adoption of digital technologies in secondary packaging is rising, with opportunities in smart labeling, real-time monitoring, and blockchain-based traceability. Biologics CDMOs are exploring smart packages embedded with QR codes, NFC tags, and sensors to track temperature and authenticity. These innovations not only ensure compliance but also enhance patient engagement and supply chain transparency. Growing investments in digital infrastructure create opportunities for CDMOs to differentiate offerings and capture contracts from global biopharma companies.

For instance, Amcor partnered with digital serialization company Kezzler to offer MaXQ, a solution for embedding unique digital codes into packaging to enable authentication, consumer interaction, and supply chain tracking.

Key Challenges

High Capital Investment Requirements

Developing compliant secondary packaging facilities involves substantial capital outlays in equipment, serialization systems, and cold chain infrastructure. Smaller CDMOs often face entry barriers due to high upfront costs, limiting competitive participation. Continuous upgrades to meet evolving regulatory mandates further strain budgets. These financial demands challenge scalability, particularly for mid-tier CDMOs aiming to expand global reach and serve high-volume biologics programs.

Complex Regulatory Landscape Across Regions

The biologics secondary packaging industry faces highly fragmented regulations, varying across North America, Europe, and emerging markets. Compliance with diverse serialization rules, labeling standards, and cold chain requirements complicates global distribution strategies. CDMOs must maintain constant vigilance and adapt operations to multiple frameworks, raising operational complexity and costs. This challenge can delay time-to-market for biologics, making regulatory adaptability a key competitive necessity.

Supply Chain Disruptions and Material Constraints

Volatility in supply chains, including shortages of specialized packaging materials, creates a major challenge. Rising costs of sustainable cartons, labels, and insulated packaging strain margins for CDMOs. Geopolitical tensions, logistics delays, and energy costs further affect availability and pricing of raw materials. These constraints threaten timely delivery of biologics, especially in cold chain-sensitive shipments, forcing CDMOs to adopt risk-mitigation strategies and diversify supplier networks.

Regional Analysis

North America

North America dominates the Global Biologics CDMO Secondary Packaging Market with a 37% share in 2024. The region’s leadership is driven by strong pharmaceutical outsourcing, advanced biologics pipelines, and strict regulatory compliance requirements. The U.S. remains the largest contributor due to extensive biologics R&D, vaccine production, and adoption of serialization technologies. Canada and Mexico provide supportive growth through expanding manufacturing and logistics capabilities. With a CAGR of 8.3%, the region is expected to nearly double its market size by 2032, supported by growing demand for cold chain and patient-centric packaging solutions.

Europe

Europe holds a 16% share in 2024, supported by a strong pharmaceutical base in Germany, France, and the UK. The region benefits from stringent packaging regulations that drive adoption of serialization, labeling, and anti-counterfeit solutions. Expansion in contract packaging services is further encouraged by a large generics and biosimilars market. Growth is moderate with a CAGR of 7.0%, reflecting a stable but competitive landscape. By 2032, Europe is projected to achieve over USD 750 million in revenue, fueled by continued biologics innovation and outsourcing trends.

Asia Pacific

Asia Pacific is the fastest-growing region, capturing 26% share in 2024 and registering a CAGR of 9.4%. China, Japan, South Korea, and India drive expansion through growing biologics manufacturing, clinical trials, and outsourcing activities. Investments in cold chain infrastructure and serialization compliance are accelerating adoption of advanced packaging solutions. Rising demand for vaccines, cell therapies, and biosimilars enhances the region’s role as a global manufacturing hub. By 2032, Asia Pacific is projected to lead growth momentum, reaching nearly USD 1.5 billion in revenue.

Latin America

Latin America contributes 4% share in 2024, with Brazil and Mexico leading demand. Growth is primarily supported by expanding pharmaceutical manufacturing capacity and increasing adoption of CDMO services. Regulatory modernization and the need for cost-effective packaging drive outsourcing trends across the region. Despite a smaller base, the market shows resilience with a CAGR of 6.5%, expected to reach nearly USD 180 million by 2032. Cold chain packaging for vaccines and biologics is emerging as a key growth driver in this region.

Middle East

The Middle East accounts for 2% share in 2024, with a steady CAGR of 5.3%. Countries such as Saudi Arabia, UAE, and Turkey invest in healthcare infrastructure and biopharmaceutical facilities, creating opportunities for CDMOs. Growth is driven by the adoption of serialization and the expansion of distribution networks for biologics. However, reliance on imports and limited manufacturing scale constrain rapid expansion. By 2032, the market is projected to surpass USD 74 million, supported by increasing government focus on healthcare security.

Africa

Africa holds 1% share in 2024, reflecting its nascent stage in the biologics CDMO secondary packaging market. South Africa and Egypt lead adoption, while the rest of the region is gradually building capacity. The region grows at a CAGR of 4.5%, supported by vaccine programs, donor-funded health initiatives, and rising pharmaceutical investments. Despite challenges such as infrastructure gaps, opportunities lie in cold chain packaging and partnerships with global CDMOs. By 2032, Africa is expected to achieve USD 49 million, highlighting steady but gradual market growth.

Market Segmentations:

By Secondary Packaging Type

Boxes
Cartons
Labels & Leaflets
Tray Packs / Clamshells
Kitting & Bundling
Serialized Packaging (Track & Trace)
Cold Chain Secondary Packaging
Others

By Compatible Primary Package Type

Ampoules
Blister Packs
Cartridges
Vials
Bottles
Prefilled Syringes
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Belgium
- Netherlands
- Austria
- Sweden
- Poland
- Denmark
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Thailand
- Indonesia
- Vietnam
- Malaysia
- Philippines
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Peru
- Chile
- Colombia
- Rest of Latin America
Middle East
- UAE
- KSA
- Israel
- Turkey
- Iran
- Rest of Middle East
Africa
- Egypt
- Nigeria
- Algeria
- Morocco
- Rest of Africa

Competitive Landscape

The Global Biologics CDMO Secondary Packaging Market is moderately consolidated, with a mix of global leaders and regional specialists competing on scale, technology, and compliance capabilities. Key players such as WuXi Biologics, FUJIFILM Diosynth, Samsung Biologics, Thermo Fisher Scientific, Catalent, Lonza, and PCI Pharma Services dominate through integrated service portfolios spanning clinical to commercial packaging. Their strengths lie in serialization expertise, cold chain packaging, and advanced kitting solutions, enabling them to meet stringent regulatory and client requirements. Mid-tier firms and regional CDMOs compete by offering cost-effective, flexible, and niche services tailored to emerging markets. Strategic partnerships, expansions in Asia-Pacific, and investments in digital packaging technologies are shaping the competitive dynamics. Growing demand for patient-centric and home-care packaging formats further intensifies rivalry, pushing companies to differentiate through innovation and end-to-end supply chain integration. The market remains dynamic, with M&A activity and infrastructure upgrades reinforcing competitive positioning globally.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Players

WuXi Biologics (Cayman) Inc.
FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
Samsung Biologics Co. Ltd.
Thermo Fisher Scientific Inc.
Catalent, Inc.
Lonza Group
PCI Pharma Services
Vetter Pharma International GmbH
Almac Group
Sharp (part of UDG Healthcare)
Recipharm AB
Siegfried Holding AG
Baxter BioPharma Solutions

Recent Developments

In March 2025, Syngene International acquired Emergent BioSolutions’ Baltimore biologics facility for US $36.5 million, boosting its bioreactor capacity and supporting biologics secondary packaging needs.
In March 2024, SMC Ltd. opened a new facility in North Carolina expanding sterile fill-finish capabilities, including secondary packaging services, reinforcing their pharmaceutical services and manufacturing footprint.
In June 2025, Zydus Lifesciences agreed to acquire Agenus Inc.’s biologics manufacturing facilities in California, marking its entry into the biologics CDMO space with potential expansion into secondary packaging services.
In April 2025, FUJIFILM Biotechnologies entered a 10-year manufacturing agreement with Regeneron Pharmaceuticals, valued at over USD 3 billion, to expand U.S. biologics production and related packaging demand.

Report Coverage

The research report offers an in-depth analysis based on Secondary Packaging Type, Compatible Primary Package Type and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Demand for biologics will increase reliance on specialized secondary packaging solutions.
Serialization and track-and-trace adoption will expand across all major regions.
Cold chain packaging will grow with rising cell and gene therapy pipelines.
Patient-centric kits will gain traction as self-administration becomes more common.
Digital and smart packaging integration will enhance compliance and transparency.
Sustainability initiatives will drive adoption of recyclable and eco-friendly packaging formats.
Outsourcing of packaging to CDMOs will deepen as pharma firms streamline operations.
Regional CDMOs will strengthen positions by offering flexible and cost-efficient services.
Strategic collaborations and acquisitions will shape market consolidation trends.
Emerging markets will become important growth hubs for packaging innovation and supply.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: BIOLOGICS CDMO SECONDARY PACKAGING FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Secondary Packaging Type

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Secondary Packaging Type & Secondary Packaging by Compatible Primary Package Type Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Biologics CDMO Secondary Packaging Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Biologics CDMO Secondary Packaging Market Export Revenue By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Biologics CDMO Secondary Packaging Market: Company Market Share

7.2. Global Biologics CDMO Secondary Packaging Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Type Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: BIOLOGICS CDMO SECONDARY PACKAGING – BY SECONDARY PACKAGING TYPE SEGMENT ANALYSIS

8.1. Biologics CDMO Secondary Packaging Market Overview by Secondary Packaging Type Segment

8.1.1. Biologics CDMO Secondary Packaging Market Revenue Share By Secondary Packaging Type

8.2. Boxes

8.3. Cartons

8.4. Labels & Leaflets

8.5. Tray Packs / Clamshells

8.6. Kitting & Bundling

8.7. Serialized Packaging (track & trace)

8.8. Cold Chain Secondary Packaging

8.9. Others

CHAPTER NO. 9: BIOLOGICS CDMO SECONDARY PACKAGING – BY SECONDARY PACKAGING BY COMPATIBLE PRIMARY PACKAGE TYPE SEGMENT ANALYSIS

9.1. Biologics CDMO Secondary Packaging Market Overview by Secondary Packaging by Compatible Primary Package Type Segment

9.1.1. Biologics CDMO Secondary Packaging Market Revenue Share By Secondary Packaging by Compatible Primary Package Type

9.2. Ampoules

9.3. Blister packs

9.4. Cartridges

9.5. Vials

9.6. Bottles

9.7. Prefilled Syringes

9.8. Others

CHAPTER NO. 10: BIOLOGICS CDMO SECONDARY PACKAGING – REGIONAL ANALYSIS

10.1. Biologics CDMO Secondary Packaging Market Overview by Region Segment

10.1.1. Global Biologics CDMO Secondary Packaging Market Revenue Share By Region

10.1.2. Region

10.1.3. Secondary Packaging Type

10.1.4. Global Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

10.1.5. Secondary Packaging by Compatible Primary Package Type

10.1.6. Global Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

CHAPTER NO. 11: NORTH AMERICA BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

11.1. North America Biologics CDMO Secondary Packaging Market Overview by Country Segment

11.1.1. North America Biologics CDMO Secondary Packaging Market Revenue Share By Region

11.2. North America

11.2.1. North America Biologics CDMO Secondary Packaging Market Revenue By Country

11.2.2. Secondary Packaging Type

11.2.3. North America Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

11.2.4. Secondary Packaging by Compatible Primary Package Type

11.2.5. North America Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

11.3. U.S.

11.4. Canada

11.5. Mexico

CHAPTER NO. 12: EUROPE BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

12.1. Europe Biologics CDMO Secondary Packaging Market Overview by Country Segment

12.1.1. Europe Biologics CDMO Secondary Packaging Market Revenue Share By Region

12.2. Europe

12.2.1. Europe Biologics CDMO Secondary Packaging Market Revenue By Country

12.2.2. Secondary Packaging Type

12.2.3. Europe Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

12.2.4. Secondary Packaging by Compatible Primary Package Type

12.2.5. Europe Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

12.3. UK

12.4. France

12.5. Germany

12.6. Italy

12.7. Spain

12.8. Russia

12.9. Rest of Europe

CHAPTER NO. 13: ASIA PACIFIC BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

13.1. Asia Pacific Biologics CDMO Secondary Packaging Market Overview by Country Segment

13.1.1. Asia Pacific Biologics CDMO Secondary Packaging Market Revenue Share By Region

13.2. Asia Pacific

13.2.1. Asia Pacific Biologics CDMO Secondary Packaging Market Revenue By Country

13.2.2. Secondary Packaging Type

13.2.3. Asia Pacific Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

13.2.4. Secondary Packaging by Compatible Primary Package Type

13.2.5. Asia Pacific Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

13.3. China

13.4. Japan

13.5. South Korea

13.6. India

13.7. Australia

13.8. Southeast Asia

13.9. Rest of Asia Pacific

CHAPTER NO. 14: LATIN AMERICA BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

14.1. Latin America Biologics CDMO Secondary Packaging Market Overview by Country Segment

14.1.1. Latin America Biologics CDMO Secondary Packaging Market Revenue Share By Region

14.2. Latin America

14.2.1. Latin America Biologics CDMO Secondary Packaging Market Revenue By Country

14.2.2. Secondary Packaging Type

14.2.3. Latin America Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

14.2.4. Secondary Packaging by Compatible Primary Package Type

14.2.5. Latin America Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

14.3. Brazil

14.4. Argentina

14.5. Rest of Latin America

CHAPTER NO. 15: MIDDLE EAST BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

15.1. Middle East Biologics CDMO Secondary Packaging Market Overview by Country Segment

15.1.1. Middle East Biologics CDMO Secondary Packaging Market Revenue Share By Region

15.2. Middle East

15.2.1. Middle East Biologics CDMO Secondary Packaging Market Revenue By Country

15.2.2. Secondary Packaging Type

15.2.3. Middle East Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

15.2.4. Secondary Packaging by Compatible Primary Package Type

15.2.5. Middle East Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

15.3. GCC Countries

15.4. Israel

15.5. Turkey

15.6. Rest of Middle East

CHAPTER NO. 16: AFRICA BIOLOGICS CDMO SECONDARY PACKAGING – COUNTRY ANALYSIS

16.1. Africa Biologics CDMO Secondary Packaging Market Overview by Country Segment

16.1.1. Africa Biologics CDMO Secondary Packaging Market Revenue Share By Region

16.2. Africa

16.2.1. Africa Biologics CDMO Secondary Packaging Market Revenue By Country

16.2.2. Secondary Packaging Type

16.2.3. Africa Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging Type

16.2.4. Secondary Packaging by Compatible Primary Package Type

16.2.5. Africa Biologics CDMO Secondary Packaging Market Revenue By Secondary Packaging by Compatible Primary Package Type

16.3. South Africa

16.4. Egypt

16.5. Rest of Africa

CHAPTER NO. 17: COMPANY PROFILES

17.1. WuXi Biologics (Cayman) Inc.

17.1.1. Company Overview

17.1.2. Secondary Packaging Type Portfolio

17.1.3. Financial Overview

17.1.4. Recent Developments

17.1.5. Growth Strategy

17.1.6. SWOT Analysis

17.2. FUJIFILM Diosynth Biotechnologies U.S.A. Inc.

17.3. Samsung Biologics Co. Ltd.

17.4. Thermo Fisher Scientific Inc.

17.5. Catalent, Inc.

17.6. Lonza Group

17.7. PCI Pharma Services

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current size of the Biologics CDMO Secondary Packaging Market?

The Global Biologics CDMO Secondary Packaging Market reached USD 2,267.62 million in 2024 and is projected to achieve USD 4,465.69 million by 2032.

What are the key segments within the Biologics CDMO Secondary Packaging Market?

Key segments in the Biologics CDMO Secondary Packaging Market include Packaging Type (Boxes, Cartons, Ampoules, Bottles) and Primary Package Type (Ampoules, Vials, Bottles, Blister Packs, Cartridges, Prefilled Syringes).

What are some challenges faced by the Biologics CDMO Secondary Packaging Market?

The Biologics CDMO Secondary Packaging Market faces challenges such as complex regulatory compliance, supply chain disruptions, and the high cost of automation and serialization infrastructure.

Who are the major players in the Biologics CDMO Secondary Packaging Market?

Major players in the Biologics CDMO Secondary Packaging Market include WuXi Biologics, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Thermo Fisher Scientific, Rentschler Biopharma, and Lonza Group.

About Author

Rajdeep Kumar Deb

Lead Analyst – Consumer & Finance

Rajdeep brings a decade of consumer goods and financial services insight to strategic market analysis.

View Profile

Related Reports

Animal Feed Protein Ingredients Market

Global Animal Protein Ingredients Market size was valued at USD 21,400.0 million in 2018 to USD 28,565.4 million in 2024 and is anticipated to reach USD 44,208.7 million by 2032, at a CAGR of 5.67% during the forecast period.

Europe Gift Card Market

The Europe Gift Card market was valued at USD XX million in 2024 and is anticipated to reach USD XX million by 2032, registering a CAGR of XX% during the forecast period.

Geographic Information Systems (GIS) Market

Geographic Information System GIS Market size was valued at USD 16.39 billion in 2024 and is anticipated to reach USD 43.17 billion by 2032, at a CAGR of 12.87% during the forecast period.

Gan And Sic Power Semiconductor Market

The gan and sic power semiconductor market size was valued at USD 765.18 million in 2024 and is anticipated to reach USD 6,183.42 million by 2032, at a CAGR of 29.85 % during the forecast period (2024-2032).

Food Fortification Ingredients Market

The Food Fortification Ingredients market size was valued at USD 56.6 Billion in 2018, increased to USD 94.4 Billion in 2024, and is anticipated to reach USD 167.0 million by 2032, growing at a CAGR of 7.33% during the forecast period.

Craniomaxillofacial Implants Market

The Craniomaxillofacial Implants market size was valued at USD 1,362.6 million in 2018, reached USD 2,195.7 million in 2024, and is anticipated to reach USD 4,248.5 million by 2032, at a CAGR of 8.66% during the forecast period.

U.S. Specialty Fats And Oils Market

U.S. Specialty Fats And Oils Market size was valued at USD 4,731.26 million in 2018 to USD 7,153.70 million in 2024 and is anticipated to reach USD 12,467.29 million by 2032, at a CAGR of 6.70% during the forecast period.

Natural Refrigerants Market

The Natural Refrigerants Market was valued at USD 1.75 billion in 2024 and is projected to reach USD 2.85 billion by 2032, growing at a CAGR of 6.3% during the forecast period.

Surgical Drainage Devices Market

The Global Surgical Drainage Devices Market is projected to grow from USD 2,413.4 million in 2024 to an estimated USD 3,902.3 million by 2032, with a compound annual growth rate (CAGR) of 6.16% from 2025 to 2032.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample